Iovance Biotherapeutics Inc (MIL:1IOVA) Share Price

Company Profile

Business description
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
Contact
825 Industrial Road
Suite 100
San CarlosCA94070
USA
T: +1 650 260-7120
E: [email protected]
https://www.iovance.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
975

Recommended

Wide moat Eli Lilly receives FDA approval for obesity pill.

Karen Andersen, CFA | 02 April 2026

These companies are our favourite choices for investors wanting to boost Aussie equity exposure.

Simonelle Mody | 02 April 2026

OpenAI, Anthropic, and Databricks are expected to go public this year at massive valuations.

Harrison Rolfes | 02 April 2026

Index	Last price	Change	% Change
All Ordinaries	8,779.40	120.30	-1.35%
CAC 40	7,981.27	164.33	2.10%
DAX 40	23,298.89	618.85	2.73%
Dow JONES (US)	46,565.74	224.23	0.48%
FTSE 100	10,364.79	188.34	1.85%
HKSE	25,017.23	276.80	-1.09%
NASDAQ	21,840.95	250.32	1.16%
Nikkei 225	52,537.15	1,202.53	-2.24%
NZX 50 Index	12,902.15	76.28	0.59%
S&P 500	6,575.32	46.80	0.72%
S&P/ASX 200	8,583.60	101.40	-1.17%
SSE Composite Index	3,927.60	20.95	-0.53%